Quantum BioPharma (NASDAQ: QNTM), a biopharmaceutical company developing therapies for neurodegenerative and metabolic disorders, has signed a Study Start-Up Agreement with the clinical research business of Thermo Fisher Scientific to implement a Phase 2 trial of Lucid-MS, its lead drug candidate for multiple sclerosis (MS). The agreement moves the innovative treatment from planning into execution, according to the company.
Most MS drugs work by quieting the immune system. Lucid-MS is designed around a novel neuroprotective approach that targets demyelination—the damage to the protective insulation around nerves—rather than solely modulating the immune system. This differentiated mechanism could offer a new way to treat MS, a chronic disease that affects millions worldwide.
Thermo Fisher’s clinical research business is a leading global contract research organization with impressive expertise in central nervous system and MS studies. The partnership aims to leverage that expertise to rigorously test Lucid-MS in a Phase 2 trial, a critical step in determining whether the drug can slow or reverse nerve damage in MS patients.
The news matters because it signals a potential shift in MS treatment strategy. While existing therapies have improved outcomes for many patients, they do not directly address demyelination, which is a hallmark of the disease and a major contributor to disability progression. By targeting demyelination, Lucid-MS could complement or provide an alternative to current immunomodulatory drugs.
Quantum BioPharma’s agreement with Thermo Fisher also underscores the company’s progress in advancing its pipeline. For investors, the Phase 2 trial represents a key milestone that could generate valuable clinical data and potentially attract further partnerships or funding. The company’s newsroom, available at https://ibn.fm/QNTM, provides ongoing updates.
InvestorWire, a specialized communications platform, noted the development in a recent release. InvestorWire is one of more than 75 brands within the Dynamic Brand Portfolio at IBN, which offers wire solutions, editorial syndication to 5,000+ outlets, and social media distribution to millions of followers. The platform also provides corporate communications solutions tailored to clients’ needs.
For more information, please visit InvestorWire. Full terms of use and disclaimers are available at https://www.InvestorWire.com/Disclaimer.
